Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacologic treatment for pain relief. TENS has been used to treat a variety of painful conditions. This review updates the basic and clinical science regarding the use of TENS that has been published in the past 3 years (ie, 2005-2008). Basic science studies using animal models of infl ammation show changes in the peripheral nervous system, as well as in the spinal cord and descending inhibitory pathways, in response to TENS. Translational studies show mechanisms to prevent analgesic tolerance to repeated application of TENS. This review also highlights data from recent randomized, placebo-controlled trials and current systematic reviews. Clinical trials suggest that adequate dosing, particularly intensity, is critical to obtaining pain relief with TENS. Thus, evidence continues to emerge from both basic science and clinical trials supporting the use of TENS for the treatment of a variety of painful conditions while identifying strategies to increase TENS effectiveness.
Introduction
Transcutaneous electrical nerve stimulation (TENS) is a commonly used nonpharmacologic and noninvasive treatment for pain. Although a number of clinical studies show the effectiveness of TENS for pain, there is still much controversy over which conditions to treat with TENS and the adequate parameters to use. Prior reports show that TENS reduces pain through both peripheral and central mechanisms. Centrally, sites in the spinal cord and brainstem that utilize opioid, serotonin, and muscarinic receptors are activated by TENS. Peripherally, at the site of TENS application, opioid and α-2 noradrenergic receptors are involved in TENS-induced analgesia [1•]. The purpose of this review is to update the reader on the latest literature concerning TENS: basic science, experimental pain, clinical trials, and systematic reviews.
TENS is the application of electrical current through electrodes placed on the skin for pain control. It can be applied with varying frequencies, from low (< 10 Hz) to high (> 50 Hz). Intensity may also be varied from sensory to motor intensities. Sensory intensity is when the patient feels a strong but comfortable sensation without motor contraction. High intensity usually involves a motor contraction but is not painful. In general, higher-frequency stimulation is delivered at sensory intensity, and low-frequency stimulation is delivered at motor intensity. Prior literature from our laboratory shows that, regardless of intensity, different frequencies activate central mechanisms to produce analgesia. Specifi cally, we show that low-frequency TENS activates μ-opioid receptors in the spinal cord and the brainstem, whereas high-frequency TENS activates δ-opioid receptors in the spinal cord and the brainstem [2] [3] [4] . Subsequent studies have investigated the role of serotoninergic, noradrenergic, muscarinic, and γ-aminobutyric acid (GABA)-ergic systems on the analgesia produced by both low-frequency and high-frequency TENS.
The terms "hyperalgesia" and "allodynia" are widely used in the following text. Hyperalgesia is an increased pain sensitivity to a peripherally applied stimulus [5] . Primary hyperalgesia is an increased pain sensitivity at the site of injury, which is thought to mirror changes in the peripheral nervous system. Secondary hyperalgesia occurs outside the site of injury, and it is thought to be mediated by changes in the central nervous system. We and others have tested the effectiveness of TENS on a variety of measures of both primary and secondary hyperalgesia.
Allodynia is defi ned as pain in response to a normally innocuous (nonpainful) stimuli or activities that are thought to be mediated by changes in the central nervous system, where activation of a peripherally located nonnociceptor is perceived as painful.
Basic Science Mechanisms

General studies
Many previous studies in rats have shown that TENS reduces secondary mechanical hyperalgesia of the paw induced by knee joint infl ammation [6•,7,8•,9,10] . More recently, Vance et al. [11•] showed that primary mechanical hyperalgesia induced by joint infl ammation was reduced in response to both high-and low-frequency TENS. Compression withdrawal threshold was decreased at 24 hours and 2 weeks following the induction of infl ammation, but not when applied at 4 hours after the induction of infl ammation. Thus, it can be suggested that because infl ammation has already completely developed, TENS inhibits primary hyperalgesia associated with infl ammation in a time-dependent manner [9] .
The site of electrode application of TENS is typically at the site of injury. However, as central mechanisms are activated by TENS, it is possible that application outside the site may also be effective. Recently, two studies confi rmed this hypothesis by showing that application of TENS to the contralateral hind limb reduces hyperalgesia of the infl amed limb [10,11•] . Furthermore, when hyperalgesia developed bilaterally after a unilateral injury, application of either high-or low-frequency TENS to the infl amed or the contralateral side reduced the hyperalgesia bilaterally [11•] . In a different pain model, Somers and Clemente [12] investigated the sites of electrode placement that would best prevent the development of allodynia in a chronic constriction injury (CCI) to the rat sciatic nerve. Repeated daily high-frequency TENS for 12 days with electrodes positioned on the skin covering either ipsilateral or contralateral paraspinal muscles reduced the development of mechanical hyperalgesia in CCI rats. Low-frequency TENS applied to acupuncture points in the ipsilateral or contralateral hind limbs decreased the development of thermal hyperalgesia, but only when TENS was delivered on the contralateral side [12] . Thus, once hyperalgesia develops, application of TENS to either the ipsilateral or the contralateral hind limb is effective.
It is generally thought that TENS produces analgesia by activation of cutaneous afferent fi bers at the site of application. However, by differentially blocking primary afferents with local anesthetics, Radhakrishnan and Sluka [8•] showed the importance of deep tissue afferents in the analgesia produced by TENS. Specifi cally, blockade of cutaneous afferents with an anesthetic cream (eutectic mixture of lidocaine and prilocaine) during TENS application had no effect on the analgesia produced by both high-and low-frequency TENS. However, when a local anesthetic was applied to the infl amed knee joint during TENS application, there was a complete blockade of the analgesic effects of TENS [8•] .
It is also generally thought that large-diameter fi bers are activated by high-frequency TENS and that low-frequency TENS at motor intensity activates Aδ afferent fi bers. Recordings of spinal cord dorsum potentials show that only large-diameter primary afferent fi bers from deep tissue are activated by both high-and low-frequency TENS at sensory intensities up to and including motor thresholds. Increasing the intensity of stimulation to twice the motor threshold recruits Aδ afferent fi bers [8•] . Thus, high intensities of stimulation well above motor threshold are needed to activate nociceptive afferents by TENS, suggesting that the analgesia produced by TENS is mediated through activation of large-diameter afferent fi bers.
TENS units have been commercialized with many different characteristics. However, little is known about whether different waveforms could infl uence TENS-mediated analgesia in a different manner [11•] compared with the effects of high-frequency TENS with different waveforms (such as an asymmetrical or symmetrical biphasic square wave) on infl ammatory hyperalgesia. Differences in waveform characteristics do not alter the analgesia produced by TENS, as hyperalgesia is similarly reduced when either an asymmetrical or symmetrical waveform is used. Therefore, different waveforms can be used to improve comfort for the patients but not to increase analgesic effi cacy.
Peripheral mechanisms
The effect of both high-and low-frequency TENS was tested in mutant mice lacking a functional α2A-adrenergic receptor (AR) against their respective wild-type counterparts. TENS-induced analgesia, at both high and low frequencies of stimulation, was reduced in α2A mutant mice compared with controls. Furthermore, when an α2 AR-selective antagonist (SK&F 86466) was administered intraarticularly, TENS-induced analgesia was reversed, but analgesia was not reversed when it was delivered intrathecally or intracerebroventricularly. Thus, it seems that peripheral α2 ARs partially contribute to TENS-mediated analgesia [7] . The α2A and α2C AR subtypes mediate antinociception when activated by the endogenous ligand norepinephrine. These receptors also produce antinociceptive synergy when activated concurrently with opioid receptors [7] .
Peripheral opioid receptors also appear to play a role in the analgesia produced by low-frequency TENS. Sabino et al. [10] showed that blockade of μ-opioid receptors at the site of application prevents the reduction in hyperalgesia produced by low-frequency TENS but not high-frequency TENS.
Spinal mechanisms
Prior reports show the importance of the opioid pathways in pain inhibition at the spinal level. A recent study showed that the inhibitory neurotransmitter GABA, but not glycine, is also involved in this analgesia at the spinal level. High-frequency, but not low-frequency, TENS applied to the infl amed knee joint increases extracellular GABA concentrations in the spinal cord dorsal horn in animals with and without joint infl ammation. Interestingly, blockade of GABA A receptors with bicuculline prevented the reduction in hyperalgesia produced by both high-and low-frequency TENS [13,14•] . In another study, spinal serotonin concentrations were increased during and immediately after treatment with low-frequency, but not high-frequency, TENS. Neither low-nor high-frequency TENS changed spinal noradrenaline concentrations [ 
Supraspinal mechanisms
Prior studies show involvement of the rostroventral medial medulla (RVM) in the hyperalgesia produced by TENS. Recently, DeSantana and Sluka [16] showed that the periaqueductal gray (PAG) also contributes to this analgesic effect. The reduction in both the primary and secondary hyperalgesia by high-and low-frequency TENS is prevented by blockade of the ventrolateral PAG with cobalt chloride. Thus, the ventrolateral PAG likely sends projections through the RVM to the spinal cord to produce analgesia. Figure 1 summarizes the main spinal and supraspinal mechanisms and receptors involved in the analgesia produced by high-and low-frequency TENS.
Tolerance to TENS
Repeated daily administration of TENS causes analgesic tolerance at spinal opioid receptors on the fourth day [17] . In the past few years, studies have investigated different strategies to improve the effi cacy of TENS by preventing or delaying the development of tolerance. Hingne and Sluka [18•] showed that blockade of N-methyl-Daspartate (NMDA) receptors during application of TENS prevents the onset of tolerance. The NMDA receptor is an ionotropic receptor for glutamate. Calcium fl ux through NMDA receptors is thought to play a critical role in synaptic plasticity, particularly central sensitization, and development of opioid tolerance. Specifi cally, TENS reversed the mechanical withdrawal thresholds on day 4 for those rats treated with MK-801 (noncompetitive NMDA receptor antagonist). Moreover, cross-tolerance at spinal opioid receptors developed in animals treated with saline but not in those treated with MK-801 (competitive antagonist to NMDA receptors) [18•] . Thus, blockade of NMDA receptors during TENS prevents the development of analgesic tolerance to TENS by preventing tolerance at spinal opioid receptors. Cholecystokinin (CCK) receptors are a group of G-protein-coupled receptors that bind the peptide hormone CCK. Blockade of CCK receptors (CCK-A or CCK-B) prevents the development of opioid tolerance. Similarly to NMDA receptor antagonists, systemic and intrathecal administration of CCK receptor antagonists prevent the development of tolerance to both high-and low-frequency TENS on day 4 when administered before TENS application in the fi rst 3 days of treatment, and also prevent the cross-tolerance to spinal opioids [19] . Interestingly, modulating the frequency of TENS between high and low frequencies delays the development of analgesic tolerance to TENS [20•] .
Basic science studies show that simultaneous activation of μ-opioid and δ-opioid receptors prevents the development of tolerance. Thus, providing low-and high-frequency TENS simultaneously, to activate μ-opioid and δ-opioid receptors, should similarly prevent tolerance to TENS. Either mixed-frequency (high-and low-frequency TENS applied at the same session, cycled every 3 seconds) or alternating-frequency (high-and low-frequency TENS applied separately in alternating days) TENS reversed mechanical hyperalgesia for 9 days. However, by day 10, repeated daily administration of either mixed-or alternating-frequency TENS became ineffective [20•] .
In summary, blockade of NMDA and CCK receptors prevents analgesic tolerance to repeated daily TENS by preventing tolerance at spinal opioid receptors [18•,19] . Furthermore, although repeated daily administration of modulating-frequency TENS leads to a development of opioid tolerance, this tolerance effect is delayed by approximately 5 days as compared with treatment with high-or low-frequency TENS [20•].
Experimental Pain in Humans
Experimental pain models have been used to retrieve useful information on electrophysical therapies prior to conducting full-scale, randomized clinical trials. However, their limitations must also be recognized in that they are unable to replicate the complex interactions between the physiologic and psychological processes of clinical pain. Five studies have been recently published on the effect of TENS on upper limb pressure, heat, and ischemic experimental pain models. Brown et al. [21•] failed to demonstrate any signifi cant differences in pain relief in a crossover study using experimental ischemic pain when high-frequency TENS (100 Hz) was applied for 5 minutes at the painful forearm site compared with a remote nonpainful site. This study used a relatively short stimulation period compared with the other experimental pain studies.
Aarskog et al. [22] used pressure pain threshold (PPT) to compare two intensity levels of high-frequency TENS (100 Hz) applied simultaneously for 20 minutes to the hand/ forearm on both sides. The intensity levels were either the lowest intensity at which the participant fi rst perceived the electrical stimulation on the skin (sensory threshold) or at a level that the participant described as strong but comfortable. There was a statistically signifi cant increase in PPT on the strong-but-comfortable intensity side but not on the sensory-threshold intensity side. The relevance of stimulus intensity was also highlighted in a study by Claydon et al. [23•] . These authors compared high-and low-frequency (4 Hz and 110 Hz), high-and low-intensity, and segmental versus extrasegmental site of stimulation on PPT recorded from the hand. Their analysis found that TENS applied to segmental and extrasegmental sites, at a high intensity (to tolerance) using different frequencies at each site, produced the greatest hypoalgesia. These results indicate that the high-intensity currents (irrespective of the applied frequency) are the key parameter in TENS applications. In a crossover study, Buonocore and Camuzzini [24] showed that high-frequency TENS (100 Hz) signifi cantly increased heat pain threshold in the area of stimulation of the superfi cial radial nerve when compared with thresholds recorded during a no-treatment control session. The increase in threshold was observed during the 10 minutes of TENS and up to 60 minutes after stimulation. Tong et al. [25•] compared high-frequency (100 Hz), low-frequency (2 Hz), and alternating-frequency (2/100 Hz) TENS applied to the forearm for 30 minutes to a control group. The alternating-frequency group produced a signifi cant increase in PPT and heat pain threshold, whereas the high-frequency group produced a signifi cant increase in PPT only. The observed changes in thresholds peaked at the end of the stimulation period (30 minutes). The superior hypoalgesic effect of mixed frequencies supports recent work conducted in rats with experimentally induced joint infl ammation. As mentioned previously, DeSantana et al. [20•] demonstrated that simultaneous administration of low-and high-frequency TENS in the same session, or alternating administration of low-and high-frequency TENS on subsequent sessions, signifi cantly delays the development of tolerance to TENS. This observation suggests an area for further exploration in humans. The key message from these studies is that high stimulus intensity and an alternating high/low frequency of TENS produced the maximal hypoalgesia using experimental pain models.
Randomized placebo-controlled trials
The ongoing questions of group classifi cation strategies, target outcome measures, and parameter selection when using TENS in humans have been addressed by several randomized placebo controlled trials. Oosterhof et al. [26• ] conducted a prospective trial comparing high-frequency (80 Hz, 50 μsec) TENS to placebo TENS to determine if there are predictive characteristics related to TENS effectiveness. One hundred and sixty-three chronic pain patients were classifi ed into three groups: osteoarthritis-related disorders; peripheral neuropathic pain; and soft tissue, bone, and visceral-related pain disorders. Pain intensity and patient satisfaction were chosen as outcome measures. The investigators concluded that patient satisfaction was related to origin of pain, and patients in the soft tissue and bone-disorders group experienced the best results. Pain intensity was not infl uenced by TENS or placebo TENS.
Narrowing the patient population appears to assist in obtaining answers to questions of TENS effectiveness, as evidenced in three studies. Warke et al. [27•] investigated the hypoalgesic effects of TENS in patients diagnosed with multiple sclerosis with a concurrent diagnosis of chronic low back pain. Ninety patients were randomly assigned to low-frequency TENS (4 Hz, 200 μsec), high-frequency TENS (110Hz, 200 μsec), or placebo TENS. Self-applied TENS treatments of 45 minutes twice daily (minimum) for 6 weeks yielded a signifi cant effect between groups over time for average low back pain. These clinically important results suggest that high-frequency TENS had its greatest effects on pain reduction during the 6 weeks of treatment. Low-frequency TENS demonstrated positive long-term results at 32 weeks. In addition, low-frequency TENS improved functional measures over the treatment period.
TENS was reported to have hypoalgesic effects in two reports of "out of hospital rescue" by emergency responders [ Visual analogue scale pain scores, anxiety scores, and heart rate response were signifi cantly reduced in the active TENS group as compared with sham TENS. Together, these two reports suggest that TENS can be used as a fast-acting pain treatment for victims of painful illnesses requiring transport for medical attention. TENS may also be benefi cial in decreasing autonomic responses to acute pain [29•] .
The issue of adjusting the stimulation intensity during the treatment session was addressed by Defrin et al. [30•] using interferential current to treat patients with knee osteoarthritis. Their fi nding of segmental, high-intensity stimulation providing a greater treatment effect than lowintensity stimulation concurs with other investigations. In addition, the fi nding that fading of the stimulation intensity during the treatment session does not impede the hypoalgesic effects suggests that despite A-fi ber adaptation, peripheral nerves remain suffi ciently activated to induce a hypoalgesic effect or that only the initial stimulation period is required to produce the treatment effect. Further investigation for minimal effective dose for the parameter of treatment time is warranted.
Recent evidence from fi ve prospective, randomized controlled studies continues to support the benefi ts of TENS for postoperative pain. DeSantana et al. [31•] tested the hypoalgesic effect of high-frequency TENS (100 Hz) applied using a strong but comfortable sensory intensity used for 30 minutes 2 and 4 hours after unilateral inguinal herniorrhaphy. TENS signifi cantly decreased analgesic requirements and incisional pain intensity for 24 hours postoperatively when compared with placebo TENS. In another study, DeSantana et al. [32•] investigated the effect of both high-and low-frequency TENS (100 Hz and 4 Hz, respectively) immediately after laparoscopic surgery for tubal ligation through placement of Yoon rings. They showed that both high-and low-frequency TENS were able to signifi cantly reduce postoperative pain. Cipriano et al. [33• ] tested a 4-hour high-frequency TENS treatment (80 Hz) with a strong but comfortable sensory intensity on 3 postoperative days following cardiac surgery and found signifi cant decreases in incisional pain both at rest and with cough when compared with placebo TENS. This decrease in pain intensity was related to positive effects on pulmonary function, with signifi cant increases in tidal volume, vital capacity, and electrical activity of the trapezius and pectoralis major muscles in patients receiving active TENS but not sham TENS.
Similar results were found when TENS was used for the more severe pain associated with thoracotomy. Solak et al. [34• ] tested low-frequency TENS (3 Hz, 100 ms, 12 mA) used for 30 minutes once a day for 10 days postoperatively and found incisional pain intensity and analgesic requirements to be signifi cantly lower compared with placebo TENS. Interestingly, the effect of TENS did not become signifi cant until the fourth postoperative day, and this effect lasted for at least 2 months postoperatively. Pulmonary function measures performed every 2 weeks for 2 months after surgery were not signifi cantly different between groups. This is in contrast to fi ndings reported by Erdogan et al. [35•] , who found that highfrequency TENS (100 Hz, 100 μs) used at a sensation to "not disturb the patient") used continuously for 48 hours postoperatively and then for 20 minutes at 3-hour intervals for 3 days increased forced expiratory volume at 1 second, forced vital capacity, and blood gas results signifi cantly more than placebo TENS at 6 to 48 hours after thoracotomy. Subjective pain levels, both at rest and during coughing, and the need for additional analgesic medication were also signifi cantly reduced in patients receiving TENS compared with placebo TENS. It appears that an adequate dose of TENS is needed to affect the severe pain associated with thoracotomy and to improve related functional performance postoperatively.
In summary, recent randomized, placebo-controlled clinical trials suggest that TENS is effective for several acute and chronic pain conditions associated with emergent and postoperative conditions. TENS is consistently more effective than placebo TENS for pain intensity, anxiety, and heart rate in these populations, and decreases in postoperative pain with cough are associated with improvements in pulmonary function when the TENS dose is adequate. Use of high-intensity stimulation and high-frequency TENS appears to be the most effective, particularly in the short term.
Meta-Analyses, Systematic Reviews, and Cochrane Reviews
Two systematic reviews and one meta-analysis have been published in the past 3 years on the effects of TENS on experimental pain models, chronic musculoskeletal pain, and chronic low back pain. Only two randomized controlled trials of TENS for chronic low back pain [36, 37] met the criteria for Khadilkar et al.'s Cochrane systematic review [38•] . Due to heterogeneity among the study populations, the authors were unable to pool the data and concluded that there was inconsistent evidence for the application of TENS for this condition.
The meta-analysis by Johnson and Martinson [39•] of electrical nerve stimulation for chronic musculoskeletal pain pooled data from 32 studies on TENS (high frequency, low frequency, variable frequency, and acupuncture-like) and 6 on percutaneous electrical nerve stimulation. There were 1227 patients with a range of conditions included in the analysis. These conditions were rheumatoid arthritis, low back pain, osteoarthritis, ankylosing spondylitis, and myofascial pain. Results from this diverse population indicated a signifi cant decrease in pain with electrical nerve stimulation compared with placebo. The authors highlighted that lack of statistical power was the main reason for disparity in their fi ndings versus other studies and meta-analyses in this area.
Chen et al. [40] reviewed studies of TENS on experimental pain with the objective of establishing the hypoalgesic effect of pulse frequency. Thirteen studies were included in their review, and only three of these studies reported a signifi cant difference for pulse frequency. The authors concluded that their review did not support the belief that pulse frequency is a key determinant of outcome when pulse intensity is standardized at a strong but comfortable level close to the painful site.
Conclusions
Basic scientifi c evidence suggests that there are peripheral and central nervous system mechanisms underlying the analgesic action of TENS. Studies also show that tolerance to repeated application of TENS can be prevented by multiple strategies, both pharmacologic and nonpharmacologic. Experimental pain studies and clinical trials are beginning to refi ne parameters of stimulation to obtain the best pain relief. It seems that stimulation intensity is a critical factor for the effectiveness of TENS. One meta-analysis was able to show the positive treatment effects of electrical stimulation for relief of chronic musculoskeletal pain, and randomized controlled trials consistently demonstrate the effectiveness of TENS for acute, emergent, and postoperative pain conditions. However, the effectiveness of TENS on individual pain conditions, such as low back pain, is still controversial, likely because of poor study designs and small sample size. Thus, continued research of TENS mechanisms and stimulation parameters in adequately characterized patient populations is critical.
